Biotech Values

[jq1234]

Consider there was one SAE from the 3 liver enzyme elevated patients in 400mg cohort, likely 200mg dose would not be a viable dose in larger population. The future of VX135 depends on if 100mg in combination with other works out. It would reduce its out license value regardless whether FDA lift the partial clinical hold IMO. I didn't think VRTX would develop VX135 on their own anyway, doesn't affect them long term to me.